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Background: Extended criteria donor (ECD) and donation after circulatory death (DCD) kidneys are at increased risk
of delayed graft function (DGF). Experimental evidence suggests that erythropoietin (EPO) attenuates renal damage
in acute kidney injury. This study piloted the administration of high dose recombinant human EPO-beta at implantation
of ECD and DCD kidneys, and evaluated biomarkers of kidney injury post-transplant.
Methods: Forty patients were randomly assigned to receive either rhEPO-b (100,000 iu) (n = 19 in the intervention
group, as 1 patient was un-transplantable post randomisation), or placebo (n = 20) in this, double blind, placebo-controlled
trial at Manchester Royal Infirmary from August 2007 to June 2009. Participants received either an ECD (n = 17) or DCD
(n = 22) kidney. Adverse events, renal function, haematopoietic markers, and rejections were recorded out to 90 days
post-transplant. Biomarkers of kidney injury (neutrophil gelatinase-associated lipocalin, Kidney Injury Molecule-1 and
IL-18) were measured in blood and urine during the first post-operative week.
Results: The incidence of DGF (53% vs 55%) (RR = 1.0; CI = 0.5-1.6; p = 0.93) and slow graft function (SGF) (32% vs 25%)
(RR = 1.1; CI = 0.5-1.9; p = 0.73) respectively, serum creatinine, eGFR, haemoglobin and haematocrit, blood pressure, and
acute rejection were similar in the 2 study arms. High dose rhEPO-b had little effect on the temporal profiles of the
biomarkers.
Conclusions: High dose rhEPO-b appears to be safe and well tolerated in the early post- transplant period in this study,
but has little effect on delayed or slow graft function in recipients of kidneys from DCD and ECD donors. Comparing
the profiles of biomarkers of kidney injury (NGAL, IL-18 and KIM-1) showed little difference between the rhEPO-b
treated and placebo groups. A meta-analysis of five trials yielded an overall estimate of the RR for DGF of 0.89
(CI = 0.73; 1.07), a modest effect favouring EPO but not a significant difference. A definitive trial based on this
estimate would require 1000-2500 patients per arm for populations with base DGF rates of 50-30% and 90%
power. Such a trial is clearly unfeasible.
Trial registration: EudraCT Number 2006-005373-22 ISRCTN ISRCTN85447324 registered 19/08/09.
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In 2011-2012, 34% of UK deceased donors were over the
age of 60 yrs while 40% were donation after circulatory
death (DCD) donors [1]. Both expanded criteria donors
(ECD) and DCD kidneys are more likely to develop de-
layed graft function (DGF) in the early post-transplant
period [2,3], with its ensuing clinical and financial im-
plications. Since its introduction, recombinant human
erythropoietin has been a major advance in the man-
agement of renal anaemia, enhancing patient cognitive
function, physical activity and quality of life [4,5]. In
addition, there is now a large body of evidence that
rhEPO has pleiotropic effects on the body beyond the
erythroid compartment. Animal studies examining acute
kidney injury, including ischaemia reperfusion injury (IRI)
have shown functional improvements [6,7], and anti-
inflammatory effects [8] after EPO administration, either
before [9,10], during [11,12], or very importantly, after the
injury has taken place [6,7,12]. In 2002, Ehrenreich et al.
[13] reported a human study in acute ischemic stroke,
where high-dose rhEPO was well tolerated and associated
with an improvement in outcome at 1 month, as assessed
by clinical endpoints of stroke and outcome scales.
Based on results from clinical trials including 1725
patients approximately 8% of patients treated with
NeoRecormon® are expected to experience adverse
reactions. Undesirable effects are observed predominantly
in patients with chronic renal failure or underlying malig-
nancies and are most commonly an increase in blood
pressure or aggravation of existing hypertension and head-
ache. The therapeutic margin of NeoRecormon® is very
wide. Even at very high serum levels no symptoms of poi-
soning have been observed [14].
Against this background of evidence supporting the
theory that administration of rhEPO after injury may be
beneficial, we performed a pilot study to assess the safety
of administering high dose rhEPO-beta to ECD and DCD
kidney recipients intra- and peri-operatively, to obtain
preliminary data on efficacy, and to evaluate changes in
three extensively reported biomarkers of kidney injury in
blood and urine: NGAL [15,16], IL-18 [17], and KIM-1
[18,19], during the first post-operative week.
Results
Patients
Eighty-two recipients were screened (Figure 1) providing
63 eligible candidates 34 donors contributed 39 kidneys,
with 5 DCD’s contributing a single kidney into both the
rhEPO-b and placebo treated groups. Thirty-nine patients
were transplanted, 19 in the rhEPO-b treated group
(one patient in the intervention arm was deemed un-
transplantable following randomisation), and 20 in the
placebo group. No difference was seen in age, sex, ethni-
city and BMI of the donor between the groups. Donorcause of death was predominantly an intra-cerebral event
in >75% of cases. The rhEPO-b group received more DCD
kidneys (63% vs 50%, p = 0.41), particularly DCD kidneys
meeting extended criteria (33% vs 20%, p = 0.65). One pa-
tient withdrew from the trial following the initial rhEPO-b
dose, due to an event attributed to an arterial intimal flap
and unrelated to the study drug, but consented to allow
continued collection of samples and follow-up data. The
patient was included in the final analysis on an intention
to treat basis. Demographics for donors and recipients are
shown in Table 1. One patient in the rhEPO-b treated
group received ATG induction, due to a weakly positive
flow cross-match in accordance with transplant unit policy.
Pre-transplant dialysis
In the rhEPO-b group 5/19 received 2 hours of haemo-
dialysis and one patient received rapid cycling peritoneal
dialysis with varying degrees of ultrafiltration immediately
prior to surgery. Of these, four patients subsequently de-
veloped DGF. In the placebo group 4/20 received 2 hours
of haemodialysis prior to surgery and all developed DGF.
Of interest, 17/21 patients on maintenance haemodialysis
prior to surgery developed DGF, as opposed to 3/15
patients on maintenance peritoneal dialysis (RR 4.05; CI
1.44-11.38; p = 0.0005).
Adverse events
There were two deaths due to sepsis in the placebo group.
Hypertension occurred in 6 rhEPO-b recipients and 5
patients in the placebo group (RR = 0.79; CI = 0.29-2.17;
p = 0.73). One patient in the rhEPO-b group developed
a generalised tonic-clonic seizure due to severe hyper-
tension, attributed to hypervolaemia and the cessation
of anti-hypertensive medication peri-operatively (unit
policy). In the opinion of the respective attending con-
sultants and the independent trial data monitor, none
of the observed adverse events was attributable to
rhEPO-b treatment.
Graft function early post-transplant
Numbers and duration of dialysis episodes were similar
in both groups (Table 2). DCD kidney recipients were
more likely to develop DGF (15/22) than ECD kidney
recipients (5/17) (RR = 2.47; CI = 1.13-5.39; p = 0.01).
Seven of 12 DCD recipients in the rhEPO-b group and
8/10 in the placebo group developed DGF (RR = 1.37;
CI = 0.77-2.42; p = 0.38). Similarly 2/7 ECD recipients
in the rhEPO-b group and 3/10 in the placebo group de-
veloped DGF (RR = 1.05; CI = 0.23-4.73; p = 1.0). The most
common indication for first dialysis was hyperkalaemia.
Graft function out to 90 days post-transplant
Sequential serum creatinine and 4-variable MDRD eGFR
are shown in Figure 2A and B respectively. Kidney
Figure 1 Screening and randomisation. 1The exclusion limit for haemoglobin was raised to 15 g/dl as a substantial amendment to the
protocol with ethical and regulatory authority approval. 2The study staff trained in the blinded sequence of delivering the intervention were not
always available for out of hours transplants.
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from baseline pre-transplant, due to the high rate of
DGF and the impact of dialysis, preventing meaningful
analysis. Acute rejection rates were similar in the rhEPO-
b treated and placebo groups during the first 3 months
post-transplant (5 vs 3; RR = 0.57; CI = 0.16-2.1; p = 0.45).
Haematological parameters
Haemoglobin levels were similar in the rhEPO-b and
placebo groups on entry into the study (11.5 ± 0.3 g/dl vs
11.3 ± 0.4 g/dl, respectively; p = 0.78). The number of
blood transfusions required during the in-patient stays
did not differ significantly between groups (p = 0.20)
and the groups had similar levels of maintenance
rhEPO-b usage post- transplant (Table 1). There was
no effect on platelet levels at any time point (data not
shown). Haemoglobin and haematocrit profiles are shown
in Figure 2C and D respectively, showing no significant
differences between the groups.
Biomarkers
The temporal profiles in blood and urine of the bio-
markers of renal injury, neutrophil gelatinase-associated
lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1)
and, IL-18 are shown in Figure 3A-E. There were smalldifferences between the rhEPO-b and placebo treated
groups, none of which reached statistical significance.
Meta-analysis of 5 trials of rhEPO in transplantation
A meta-analysis (Figure 4) including data from this trial
and from those described by Sureshkumar et al. [20],
Hafer et al. [21], Martinez et al. [22] and Aydin et al.
[23] yielded an overall estimate of the RR for DGF of
0.89 (CI = 0.73; 1.07), a modest effect favouring rhEPO,
but not demonstrating a significant difference between
rhEPO and placebo treatments.
Discussion
This pilot study supported the view that the intra- and
peri-operative intra-venous administration of high dose
rhEPO-b (a total infusion of 100,000 iu of rhEPO-beta)
appeared to be safe in the early post-transplant period.
The study reports only small effect sizes of rhEPO-b on
adverse events, renal function, haematopoietic factors,
acute rejection episodes, and the profiles of biomarkers
of kidney injury post-transplant.
The dose regimen in our study was adapted from
Ehrenreich et al. [13], where high levels of EPO were re-
quired to cross the blood-brain barrier to provide a high
concentration in the cerebrospinal fluid. In renal patients,
Table 1 Demographics of donors and recipients






age (yrs) median(IQR) 52 (45-58) 53 (46-66)
male n (%) 10 (53%) 13 (65%)
ethnicity white n (%) 19 (100%) 20 (100%)
Cause of death n (%)
intra-cranialhaemorrhage 14 (74%) 14 (70%)
other intra-cranial event 1 (5%) 4 (20%)
extra-cranial event 4 (21%) 2 (10%)
Donated kidney
ECD kidney n (%) 7 (37%) 10 (50%)
DCD kidney n (%) 12 (63%) 10 (50%)
inotropic support n (%) 12 (63%) 16 (80%)
vasopressin n (%) 9 (47%) 11 (55%)
final creatinine (μmol/L) median(IQR) 61(51-87) 77(66-96)
warm ischaemic time1 mins (range) 17 (12-22) 17 (13-20)
DCD only
Recipients (n = 40)
Demographics
age (yrs) median(IQR) 51 (43-63) 54 (41-63)
male n (%) 10 (53%) 14 (70%)
White 13 (68%) 19 (95%)
Asian 5 (27%) 1 (5%)
Afro-Caribbean 1 (5%) 0
BMI median(IQR) 25 (23-27) 25 (23-29)
Cause of ESRD n (%)
glomerular disease 8 (42%) 6 (30%)
hypertension 1 (5%) 3 (15%)
reflux nephropathy 4 (21%) 3 (15%)
other 6 (32%) 8 (40%)
Mode of dialysis pre-transplant n (%)
haemodialysis 9 (47%) 12 (60%)
peritoneal dialysis 8 (42%) 7 (35%)
pre-dialysis 2 (11%) 1 (5%)
months on dialysis median(IQR) 30 (16-51) 42 (22-52)
previous transplant n (%) 3 (16%) 5 (25%)
anuric pre-transplant n (%) 6 (32%) 7 (35%)
diabetes n (%) 1 (5%) 0
hypertension n (%) 17 (90%) 17 (85%)
rhEPO pre-transplant n (%) 17 (90%) 17 (85%)
days before transplant of last rhEPO
median (IQR)
5 (4-11.5) 4.5 (1.8-11.0)










Cold ischaemic time hrs.mins (range) 16.52 16.45
(12.19-32.36) (11.12-28.42)
EPO maintenance post-transplant n(%) 9 (46%) 11 (55%)
Blood transfusions post-transplant (n) 6 11
Packed red cell post-transplant (units) 1.2 ± 0.5 1.9 ± 0.6
Acute rejection episodes in 3 mths
post-transplant
5 3
1warm ischaemic time in DCD was defined as the time from asystole to in-situ
cold perfusion.
IQR = interquartile range, BMI = body mass index, ESRD = end stage renal
disease, PRA = panel reactive antibodies.
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iu/kg/week [24], which in the average 70 kg patient, is
half the dose administered in this study. Furthermore,
mathematical modelling in healthy volunteers has demon-
strated that a similar dose (1000 U/kg) resulted in >98%
occupation of EPO receptors, which persisted for 2 days
following the dose [25]. The majority of the recipients in
this study were receiving maintenance rhEPO for anaemia
associated with end-stage renal failure, though administra-
tion of rhEPO stopped more than 2 days prior to trans-
plant in all but 7 recipients. It is conceivable that tissue
protection was afforded by low levels of rhEPO to both
groups, and thus confounded the outcome, with a dose
ceiling effect for EPO. However, the retrospective review
from Mohiuddin et al. [26] of patients receiving anaemia
maintenance doses of rhEPO at the time of transplant-
ation found no difference in the DGF rate or haemoglobin
levels compared to those patients not receiving rhEPO,
out to three months post-transplant.
Song et al. [27] administered 300 mg/kg of erythro-
poietin-beta IV to 36 adults undergoing coronary artery
bypass grafting at induction of anaesthesia and noted a re-
duction in the incidence of acute kidney injury (EPO 8%
vs Placebo 29%, p = 0.03), defined as a 50% increase in
serum creatinine over baseline in the first 5 post-operative
days. However Poulsen et al. [28] examined the effect of
high dose EPO (500 iu/kg IV 12-18 hrs pre-op and at in-
duction) in patients undergoing coronary artery bypass
with no apparent difference between treatment and pla-
cebo groups with regard to serum creatinine. Martinez
Table 2 Graft function and dialysis early post-transplantation
rhEPO-b group (n = 19) Placebo group (n =20) RR (CI) p
Primary non-function 0 0
Delayed graft function n (%) 10 (53%) 11 (55%) RR = 1.0 (0.5-1.6) p = 0.93
Slow graft function n (%) 6 (32%) 5 (25%) RR = 1.1 (0.5-1.9) p = 0.73
Days to first dialysis* 1 (1-3) 1 (1-3)
Number of dialysis episodes* 3 (1-17) 4 (1-19)
Days to last dialysis* 7 (1-41) 8 (1-35)
*median (IQR).
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examined the effect of 40,000U EPO IV administered
before kidney transplantation, at 12 hours, 7 days and
14 days post-operatively on the incidence of DGF [22].
There was no difference in DGF rates between the
groups (EPO 32% vs placebo 29%), with similar eGFRs
at 1 month post-implantation. A retrospective study in
France compared recipients on 250 U/kg/week of EPO
at the time of transplantation to recipients not receiving
EPO and found no difference in graft function or
haemoglobin level at 1 month [29]. Furthermore, the
German multi-centre EPO Stroke Trial, a Phase II/III
trial designed to reproduce the promising results of the
earlier EPO Stroke Study (improved clinical recovery in
EPO treated patients with ischemic stroke), was a negative
trial that also raised safety concerns [30]. Aydin et al.Figure 2 Sequential serum creatinine, 4-variable MDRD eGFR, haemo
(4v MDRD). Renal function was similar in the EPO and placebo treated patien
during the first 3 months post-transplant. Haematocrit levels were similar in th
treated group placebo group Data expressed as mean ± SEM, ANOVA.[23] reported a 12-month, randomized, double-blind,
placebo- controlled trial of high-dose recombinant hu-
man erythropoietin-b (Epoetin) in 92 donation after
cardiac death kidney transplant recipients. Patients were
randomized to receive an intravenous bolus of Epoetin
(3.3 × 104 IU; n = 45) or placebo (saline 0.9% solution;
n = 47) on 3 consecutive days, starting 3–4 h before the
transplantation and 24 h and 48 h after reperfusion.
Results showed no differences in the incidence or duration
of delayed graft function and/or primary non-function
(Epoetin 77.8 vs. placebo 78.7%, p = 1.00) though Epoetin
treatment significantly increased the risk of thrombotic
events at 1 month and 1 year (Epoetin 24.4% vs. placebo
6.4%, p = 0.02).
In patients with an acute ST-segment elevation myocar-
dial infarction a single intravenous bolus of EPO-alphaglobin and haematocrit profiles. (A) serum creatinine and (B) eGFR
ts, with no significant differences. (C) Haemoglobin and (D) Haematocrit
e EPO and placebo treated patients with no significant differences. EPO
Figure 3 Biomarkers of kidney injury (A) uNGAL ng/mgCr (B) pNGAL (ng/ml) (C) uIL-18 pg/mgCr (D) pIL-18 (ng/ml) (E) uKIM-1 pg/mgCr.
rhEPO treated group placebo group Data shown as means +/- SEM. P values are for an overall difference between EPO and placebo treated,
based on a mixed-effect ANOVA model.
Figure 4 A meta-analysis of 5 randomised controlled trials of the effect of high dose EPO on DGF represented as a Forest plot.
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not reduce infarct size [31].
Two other randomised controlled trials investigating
high dose EPO in renal transplantation have been pub-
lished recently. Sureshkumar et al. [20] conducted a
randomised double blind clinical trial where the primary
end point was the level of graft function in the early post-
transplant period. Thirty-six patients in each group were
included in the final analysis and their data gave similar
event rates to the study reported here, with a RR for DGF
of 0.88 (0.53-1.48). There were no clinically demonstrable
beneficial effects of high dose EPO-alpha given intra-
arterially during the early reperfusion phase in deceased
donor kidney recipients, in terms of reducing the inci-
dence of DGF or improving short-term allograft function.
The authors also measured two biomarkers (NGAL and
IL-18) post transplantation and found similar levels in the
EPO treated group versus the control group. They did not
report an increase in adverse events in the EPO treated
group.
In the second study Hafer et al. [21] evaluated high
dose EPO-alpha administered intra-and post-operatively
to recipients of deceased donor kidneys, with a primary
study end point of allograft function 6 weeks post-
transplant. The study recruited 45 patients to each arm.
There was no significant effect of EPO-alpha on either
long-term graft function (eGFR at 12 months) or histology
(protocol biopsies at 6 weeks and 6 months), with a RR
for DGF again similar to our study at 0.71 (0.36-1.43), but
with a lower overall event rate of 27%.
The doses of rhEPO used by Sureshkumar et al.
(40,000 iu rhEPO-alpha injected into the iliac artery)
and Hafer et al. (3 doses of 40,000 iu rhEPO-alpha) were
similar to our study (3 doses of 33,000 iu rhEPO-beta).
It is conceivable that a lack of efficacy is a consequence
of the timing of EPO administration. Injury prior to re-
perfusion is multi-factorial and due to recurrent insults
to the kidney rather than a single ischaemia reperfusion
event. Typically injury begins with peri-mortem events
including, severe hypertension or hypotension and
nephrotoxic agents. Retrieval of the kidneys is associated
with warm ischaemia, cold ischaemia and the anastomotic
ischaemic phase. The lack of efficacy in these studies may
be due to the delay in rhEPO-b administration until reper-
fusion. However, therapeutic intervention in the donor,
prior to organ retrieval and storage, would impact on all
organs donated and prevent any potential recipients from
declining involvement in the study without declining
organ transplantation. It was not possible to intervene
during cold storage firstly because we did not have access
to machine perfusion technology at the time, and secondly
the potential recipient would not have been able to decline
involvement in the study. We decided to intervene im-
mediately prior to reperfusion, with the knowledge thatsignificant injury to the kidney may have already occurred,
but based on the experimental evidence, intervention
could still be beneficial to the graft. The participants in
our study received kidneys from DCD and ECD donors.
In the study from Sureshkumar et al. the kidneys were
from ECD donors in only 46% of the cases. The donor
details were not presented in the study from Hafer et al.,
though their exclusion criteria included immunological
loss of a previous graft, and cold ischaemic time of longer
than 24 hours.
Conclusions
Taking the five studies together, a range of quality of
donated kidneys has been examined and the evidence
appears convincing that high dose rhEPO in deceased
kidney transplants, although well tolerated, has little
effect on DGF, early or later allograft function, graft hist-
ology, or levels of biomarkers of kidney injury, including
NGAL, IL-18 and KIM-1. Additionally, concerns were
raised over the increased number of thrombotic events
in the EPO treated groups in some of the trials. A meta-
analysis of the five trials yielded an overall estimate of
the RR for DGF of 0.89 (CI = 0.73; 1.07), a modest effect
favouring EPO but not demonstrating a significant differ-
ence. At a time when there is obvious need to maximise
the lifespan of donated organs it is disappointing that the
promising experimental evidence of rhEPO tissue protec-




The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and was consist-
ent with the International Conference on Harmonization
of Good Clinical Practice. The clinical and research activ-
ities reported are consistent with the Principles of the
Declaration of Istanbul as outlined in the Declaration of
Istanbul on Organ Trafficking and Transplant Tourism.
The study was approved by the Central Manchester
Research Ethics Committee (07/Q1407/94), the Medicines
for Human use Regulatory Authority (EuDract no.
2006-005373-22), and registered with the ISRCTN
(number 85447324; 19/08/09). Informed consent was
obtained from each patient. The manuscript adheres to
CONSORT guidelines for reporting clinical trials [32].
Patients
Patients were eligible if aged 18 years or more, able to
give consent, and in receipt of a Maastricht category III,
(awaiting cardio-circulatory death after withdrawal of
treatment), a Maastricht category IV (cardio-circulatory
death in a brain dead donor), a kidney from an extended
criteria donor (defined as equal to or greater than 60 years
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accident, hypertension or serum creatinine greater than
133 μmol/l, or a kidney with a cold ischaemic time greater
than 24 hours). Exclusion criteria included inability to
consent, pregnancy, breastfeeding, acute infection, pre-
vious intolerance of the trial drug, a diastolic blood
pressure > 100 mm/Hg pre-transplantation, or initially
a haemoglobin level = or > 13 g/dl. However, it became
clear that a haemoglobin cut-off of 13 g/dl would exclude
approximately one third of otherwise eligible participants.
A review of the pre-operative haemoglobin levels of adults
transplanted at this centre in 2007 reported a mean pre-
op haemoglobin of 12.2 g/dl, with a range of 7.4-17.7 g/dl,
and a mean decrease of 2.4 g/dl within 24 hours of sur-
gery. As a result, the haemoglobin exclusion criterion was
reset to ≥15 g/dl, as a substantial amendment to the
protocol with ethical and regulatory authority approval.
All patients received immunosuppression as per unit
protocol. Induction immunosuppression consisted of
basiliximab 20 mg intravenously on day 0 and day 4, as
well as a single dose of methylprednisolone 1 g given
intra-operatively. Maintenance immunosuppression con-
sisted of tacrolimus (Prograf®), prednisolone and myco-
phenolate mofetil (Cellcept®). DGF was defined as the
need for haemodialysis or peritoneal dialysis within the
first seven days post transplantation, and slow graft
function was defined as a creatinine reduction ratio at
day 7 of <70% [33].
Randomisation and blinding
Eligible patients were randomly assigned by the trial
Pharmacy using a computer-generated list to receive
either rhEPO-b (Neorecormon® Roche) or 0.9% saline.
All study participants and the clinical team were
blinded to the trial drug for the duration of the study.
Pharmacovigilance was undertaken by PDMS Roche
Products Limited.
Sample collection and processing
The first dose of rhEPO-b (33,000 iu) (Neorecormon®
Roche) or 0.9% saline were administered intra-operatively
in a 100 ml intra-venous infusion over 15 minutes, as
clamps were released to allow graft reperfusion. The sec-
ond and third infusions (each 33,000 iu) were given at
24 hour intervals post-operatively, making a total rhEPO-
b dose of approximately 100,000 iu over approximately
48 hours. Prior to reperfusion, a 20 ml systemic blood
sample was collected via the central line (the pre-
reperfusion sample). The post-reperfusion 20 ml blood
sample was collected approximately 15 minutes follow-
ing reperfusion. 10 ml blood samples were collected at
2, 8 and 24 hours, and daily for the first 7 days post-
operatively, coinciding with venepuncture for routine
care where possible. Blood samples were centrifuged at2000 rpm for 10 minutes to separate the plasma, which
was aliquoted and stored at -80C. Urine samples were
collected at similar time points where possible, centrifuged
at 2000 rpm for 5 minutes, aliquoted and stored at -80C.
Samples were batched for analysis of biomarkers.
Measurement of biomarkers
Plasma NGAL (pNGAL) and urine NGAL (uNGAL)
were measured by immunoassay using the Duoset
DY1757, and urine KIM-1 (uKIM-1) using the duoset
DY1750, R&D Systems, OXON UK, following the
manufacturer’s guidelines. Mature IL-18 in plasma and
urine was measured using an in-house immunoassay
(capture antibody - Clone 125-2H, detection antibody -
Clone 159-12B, and standard - rHuIL-18, MBL, Medical
and Biological Labs co. Ltd, Nagoya, Japan). Sample
concentrations in all assays were calculated from a 4-
parameter standard curve (SOFTmax PRO v4 software,
Molecular Devices, Ca 94089). Biomarkers in urine were
corrected for creatinine concentration in the sample.
An internal standard was included on each assay plate
confirming an inter-assay coefficient of variation (CV)
of <20% and an intra-assay CV of <10%.
Sample size and statistical analysis
As a pilot, the study had no formal power calculation,
but was designed to test the safety of delivering the
intervention, to describe effect sizes on the measured
variables (adverse events, renal function, haematopoietic
markers, and acute rejection episodes), and to evaluate
the profiles of three biomarkers of kidney injury. A sam-
ple size of 20 per arm was chosen on the basis of feasi-
bility and to gather sufficient data to design and power a
definitive trial [34].
Data analysis was performed using GraphPad Prism 5.
Results were presented as median ± interquartile range,
or as percentages as appropriate. Mann-Whitney U tests
were used to compare continuous variables between
groups. Categorical data was analysed using a Fisher’s
exact test to generate a risk ratio (RR) and confidence
interval (CI). Clinical and biomarkers assessed at mul-
tiple times were compared using mixed-effect ANOVA
models to allow for correlations between repeat mea-
sures using the lmer package in the R statistical environ-
ment [35]. A meta-analysis including this trial and those
described by Sureshkumar et al. [20], Hafer et al. [21],
Martinez et al. [22] and Aydin et al. [23] was conducted
to derive a pooled RR estimate using the Mantel-
Haenszel estimator and a random effects estimator, and
the meta package in R. A two- tailed significance level
of 0.05 was used throughout.
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